Kaveri Pohlman
Stock Analyst at Clear Street
(3.84)
# 1,913
Out of 5,014 analysts
230
Total ratings
36.3%
Success rate
6.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Reiterated: Buy | $28 | $9.88 | +183.40% | 5 | Sep 30, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $38 | $8.27 | +359.49% | 1 | Sep 29, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $131 | $83.29 | +57.28% | 5 | Sep 23, 2026 | |
| EVMN Evommune | Reiterated: Buy | $28 → $23 | $8.26 | +178.45% | 4 | Sep 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $99 | $31.27 | +216.60% | 3 | Sep 8, 2026 | |
| JBIO Jade Biosciences | Rated: Buy | $25 → $48 | $14.04 | +241.88% | 3 | Sep 4, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $173 | $140.89 | +22.79% | 7 | Aug 31, 2026 | |
| LBRX LB Pharmaceuticals | Rated: Buy | $45 → $69 | $38.37 | +79.83% | 2 | Aug 21, 2026 | |
| CGEM Cullinan Therapeutics | Rated: Buy | $46 → $47 | $15.35 | +206.19% | 20 | Aug 14, 2026 | |
| ELVN Enliven Therapeutics | Rated: Buy | $55 → $68 | $45.84 | +48.34% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.63 | +453.85% | 2 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $16.91 | +83.32% | 1 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $11.70 | +498.29% | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $29 | $14.32 | +102.51% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $533 → $680 | $503.84 | +34.96% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.35 | +788.89% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $14.66 | +36.43% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $220 | $137.93 | +59.50% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $17.28 | -30.56% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $8.78 | +105.01% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $4.16 | +332.69% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $5.60 | +114.29% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $47 | $30.28 | +55.22% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $58.41 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $35.68 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.86 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.33 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.83 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.24 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.82 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.95 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $1.95 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $2.72 | n/a | 3 | Jul 6, 2022 |
Sagimet Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $28
Current: $9.88
Upside: +183.40%
Q32 Bio
Sep 29, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $8.27
Upside: +359.49%
Oruka Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $131
Current: $83.29
Upside: +57.28%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $28 → $23
Current: $8.26
Upside: +178.45%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $99
Current: $31.27
Upside: +216.60%
Jade Biosciences
Sep 4, 2026
Rated: Buy
Price Target: $25 → $48
Current: $14.04
Upside: +241.88%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $173
Current: $140.89
Upside: +22.79%
LB Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $45 → $69
Current: $38.37
Upside: +79.83%
Cullinan Therapeutics
Aug 14, 2026
Rated: Buy
Price Target: $46 → $47
Current: $15.35
Upside: +206.19%
Enliven Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $45.84
Upside: +48.34%
Aug 3, 2026
Reiterated: Buy
Price Target: $9
Current: $1.63
Upside: +453.85%
Aug 3, 2026
Reiterated: Buy
Price Target: $31
Current: $16.91
Upside: +83.32%
Jun 22, 2026
Reiterated: Buy
Price Target: $70
Current: $11.70
Upside: +498.29%
May 7, 2026
Reiterated: Buy
Price Target: $21 → $29
Current: $14.32
Upside: +102.51%
May 6, 2026
Reiterated: Buy
Price Target: $533 → $680
Current: $503.84
Upside: +34.96%
Mar 31, 2026
Reiterated: Buy
Price Target: $12
Current: $1.35
Upside: +788.89%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $14.66
Upside: +36.43%
Mar 2, 2026
Reiterated: Buy
Price Target: $200 → $220
Current: $137.93
Upside: +59.50%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $17.28
Upside: -30.56%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $8.78
Upside: +105.01%
Dec 1, 2025
Reiterated: Buy
Price Target: $18
Current: $4.16
Upside: +332.69%
Nov 26, 2025
Reiterated: Buy
Price Target: $12
Current: $5.60
Upside: +114.29%
Nov 11, 2025
Reiterated: Buy
Price Target: $32 → $47
Current: $30.28
Upside: +55.22%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $58.41
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $35.68
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.86
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.33
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $25.83
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $13.24
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $6.82
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $24.95
Upside: n/a
Apr 29, 2024
Reiterated: Buy
Price Target: $21
Current: $1.95
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $2.72
Upside: n/a